Evidence map›Paper›PMID 42186262›Full record

ArticleJournal of medicinal chemistry2026

First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models.

Alessandra Fiore, Antonio Scarano, Giulia Antonini, Alexandra Ioana Corfù, Lea Sicuro, Serena Faggiano, Adriana Celesia, Chiara Tesoriero, Raffaella Pacchiana, Andrea Vettori and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alessandra FioreDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, 37134 Verona, Italy.
Antonio ScaranoDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 23/a, 43124 Parma, Italy.ORCID 0009-0008-4034-1703
Giulia AntoniniDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.ORCID 0000-0002-4991-8731
Alexandra Ioana CorfùDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.ORCID 0009-0001-6733-1459
Lea SicuroDepartment of Medical Biotechnologies and Translational Medicine c/o L.I.T.A/University of Milan, Via F.lli Cervi 93, 20090 Segrate (MI), Italy.
Serena FaggianoDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 23/a, 43124 Parma, Italy.ORCID 0000-0002-7447-9945
Adriana CelesiaDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, 37134 Verona, Italy.
Chiara TesorieroDepartment of Biotechnology, University of Verona, 37134 Verona, Italy.
Raffaella PacchianaDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, 37134 Verona, Italy.
Andrea VettoriDepartment of Biotechnology, University of Verona, 37134 Verona, Italy.
Liaisan ArslanbaevaDepartment of Experimental Oncology, IEO European Institute of Oncology IRCSS, 20139 Milan, Italy.
Saverio MinucciDepartment of Experimental Oncology, IEO European Institute of Oncology IRCSS, 20139 Milan, Italy.
Isabella PallaviciniDepartment of Experimental Oncology, IEO European Institute of Oncology IRCSS, 20139 Milan, Italy.
Luca MollicaDepartment of Medical Biotechnologies and Translational Medicine c/o L.I.T.A/University of Milan, Via F.lli Cervi 93, 20090 Segrate (MI), Italy.ORCID 0000-0001-5403-9507
Lucia TamboriniDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.ORCID 0000-0002-9755-7846
Massimo DonadelliDepartment of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, 37134 Verona, Italy.ORCID 0000-0001-9224-9230
Paola ContiDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.ORCID 0000-0003-2140-0567
Stefano BrunoDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 23/a, 43124 Parma, Italy.
Chiara BorsariDepartment of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.ORCID 0000-0002-4688-8362

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, driven by metabolic reprogramming. Since direct glycolytic enzyme inhibition is limited by toxicity, indirect glycolysis modulation through inhibition of the kinase activity of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) may offer a safer therapeutic strategy. Herein, we report the first-in-class covalent PFKFB3 inhibitor (

Indexed as

Antineoplastic AgentsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsPhosphofructokinase-2Protein Kinase InhibitorsAnimalsCell Line, TumorCell ProliferationDrug DiscoveryHumansStructure-Activity RelationshipZebrafishAntineoplastic AgentsPFKFB3 protein, humanPhosphofructokinase-2Protein Kinase Inhibitors

Identifiers

PMID42186262
PMCPMC13266998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.